Pharmaceutical company
Appears in 13 stories · Last updated Nov 9, 2026
Developer of RYBREVANT FASPRO; FDA granted accelerated approval for advanced head and neck cancer on November 6, 2026; Phase 3 OrigAMI-5 ongoing
The U.S. Food and Drug Administration granted accelerated approval on November 6 to RYBREVANT FASPRO, the subcutaneous form of amivantamab, for advanced head and neck cancer. The decision follows a 77% confirmed response rate for a first-line combination of amivantamab, pembrolizumab and carboplatin in 22 patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma, reported at ESMO 2026.
Updated 2 days ago
Developer of JNJ-6143; presented Phase 1 data at ESMO 2026
Johnson & Johnson's experimental prostate cancer drug JNJ-6143 shrank tumors in 12 of 16 patients with measurable disease in a Phase 1 trial. The results were presented October 24 at the European Society for Medical Oncology Congress, and J&J's press release followed a day later.
Updated 3 days ago
Developer and marketer of ICOTYDE; approved in the US, EU and UK for plaque psoriasis, with positive phase 3 results reported in psoriatic arthritis and versus Stelara
The UK approved ICOTYDE (icotrokinra) on October 23 for adults and adolescents 12 and older weighing at least 40 kilograms. The drug is the first oral peptide that blocks the IL-23 receptor, taken as one 200 mg tablet a day, and is also cleared in the US and European Union. Two-year ICONIC-LEAD data presented October 9 showed at least 72% of patients held at least 90% skin clearance at week 112.
Updated 4 days ago
Holds commercial rights to Darzalex; competes in head and neck cancer
Genmab's experimental head and neck cancer drug, petosemtamab, cut the risk of death in half when added to Merck's Keytruda in a late-stage trial. Shares hit a record on October 28, the company's third late-stage win in quick succession. Analysts at William Blair called the data 'exceedingly positive.'
Updated Nov 1
Markets Tremfya, which had subcutaneous Crohn's induction first
Since 2022, adults with moderately to severely active Crohn's disease have started Skyrizi with three intravenous infusions at weeks 0, 4 and 8, usually at a clinic. On October 23, the Food and Drug Administration approved a second path: 720 milligrams injected under the skin at weeks 0, 2, 4 and 8, given at home with an on-body injector.
Licensor of RAP-219 to Rapport
Rapport Therapeutics' epilepsy pill beat placebo in a mid-stage bipolar mania trial, the company said Oct. 20. The 3.1-point gap on a 60-point mania scale was statistically significant, but it missed the four points chief executive Abraham Ceesay had called clinically meaningful.
Updated Oct 26
Developer and marketer of ERLEADA (apalutamide)
Apalutamide taken for six months before and after prostate cancer surgery cut the risk of recurrence or death by 62% compared with surgery alone in a 408-patient substudy of the PROTEUS trial. Johnson & Johnson reported the results on Oct. 24, 2026; they were presented at the ESMO Congress in Madrid and accepted for publication by European Urology.
As of September 2026: Competitor; has withdrawn Linx from non-U.S. markets
The Food and Drug Administration approved Implantica's RefluxStop device on August 20, clearing the way for the first new anti-reflux implant to enter the U.S. market since Johnson & Johnson's Linx. On September 29, the company kicked off its commercial launch at the American Foregut Society's annual meeting in Washington, drawing an over-capacity crowd of more than 120 surgeons and gastroenterologists. The launch venue was chosen to put the device in front of the specialists who decide which reflux patients get surgery.
Updated Sep 29
As of September 2026: Competitor whose rival XLRP therapy failed
X-linked retinitis pigmentosa gradually destroys the retinas of young men, and no treatment has ever slowed it. Beacon Therapeutics' gene therapy laru-zova is now the first to clear a pivotal trial, and the company says it will file for US approval later this year.
Updated Sep 21
As of September 2026: Current first-line standard via Rybrevant plus chemotherapy
Patients with EGFR exon 20 insertion lung cancer have had almost no targeted options in the front-line setting. A phase 3 trial presented Sept. 13 in Seoul changed that. Adding the oral drug zipalertinib to chemotherapy delayed tumor progression by six months compared with chemotherapy alone.
Updated Sep 13
As of July 2026: Incumbent competitor
Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, about $2.8 billion, with up to $1 billion more if two drugs hit development targets. The purchase pulls one of the world's largest drugmakers into psychedelic medicine.
Updated Jul 16
As of May 2026: Developer and commercial partner for ICOTYDE
For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.
Updated May 30
As of May 2026: Defendant; won reversal on implied covenant but owes damages for efforts breach
Delaware's courts rule on American corporate disputes. On January 12, 2026, the state's Supreme Court decided that when a merger agreement specifies a particular path to an earnout payment, courts won't rescue sellers who failed to negotiate alternatives.
Updated May 26
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
